GP73 contributes to the sensitivity of cisplatin in esophageal cancer

Background The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases. Methods Using microarray analysis, we identified GP73 as a candidate gene th...

Full description

Saved in:
Bibliographic Details
Published in:Esophagus : official journal of the Japan Esophageal Society 2009-09, Vol.6 (3), p.173-176
Main Authors: Katada, Takeyasu, Ishiguro, Hideyuki, Kimura, Masahiro, Mitui, Akira, Harata, Koshiro, Ogawa, Ryo, Kuwabara, Yoshiyuki
Format: Article
Language:English
Subjects:
Esophageal cancer
Esophagus
Gastroenterology
Medical prognosis
Medicine
Medicine & Public Health
Original Article
Surgical Oncology
Thoracic Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The prognosis of esophageal cancer patients is poor. Cisplatin (CDDP) is most often used for advanced esophageal cancer; however, the emergence of drug resistance has prevented successful treatment in many cases. Methods Using microarray analysis, we identified GP73 as a candidate gene that is overexpressed in TE4, an esophageal cancer cell line which is highly resistant to CDDP. We downregulated GP73 expression in TE4 using siRNA methods. To determine the effect of reduced GP73 expression on the proliferation of TE4, we used cytotoxicity assays. Results Downregulation of GP73 expression using siRNA induced a significant decrease in the IC 50 compared with cells treated with either control siRNA or mock transfection. Conclusions GP73 is a candidate gene in esophageal cancer that may be the target of future molecular-targeted therapy in combination with CDDP.
ISSN:1612-9059
1612-9067
DOI:10.1007/s10388-009-0201-4